Display options
Cite
Filippini G, Del Giovane C, Clerico M, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017;4:CD012200doi: 10.1002/14651858.CD012200.pub2.
Filippini, G., Del Giovane, C., Clerico, M., Beiki, O., Mattoscio, M., Piazza, F., Fredrikson, S., Tramacere, I., Scalfari, A., & Salanti, G. (2017). Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane database of systematic reviews, 4CD012200. https://doi.org/10.1002/14651858.CD012200.pub2
Filippini, Graziella, et al. "Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis." The Cochrane database of systematic reviews vol. 4 (2017): CD012200. doi: https://doi.org/10.1002/14651858.CD012200.pub2
Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. PMID: 28440858; PMCID: PMC6478290.
Copy Download .nbib Format: NLM
Share it on

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

The Cochrane database of systematic reviews

Graziella Filippini, Cinzia Del Giovane, Marinella Clerico, Omid Beiki, Miriam Mattoscio, Federico Piazza, Sten Fredrikson, Irene Tramacere, Antonio Scalfari, Georgia Salanti

Affiliations

  1. Scientific Direction, Fondazione IRCCS, Istituto Neurologico Carlo Besta, via Celoria, 11, Milan, Italy, 20133.
  2. Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy, 41124.
  3. University of Turin, Division of Neurology, AOU San Luigi Gonzaga, Regione Gonzole, 13, Orbassano, Torino, Italy, 10043.
  4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 17177.
  5. Department of Epidemiology and Biostatistics, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  6. Department of Medicine, Division of Brain Sciences, Centre for Neuroscience, Wolfson Neuroscience Laboratories, Imperial College London, Du Cane Road, London, UK, W12 0NN.
  7. Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, Bern, Switzerland, 3005.

PMID: 28440858 PMCID: PMC6478290 DOI: 10.1002/14651858.CD012200.pub2

Abstract

BACKGROUND: The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease-modifying drugs in the mid-1990s heralded a period of rapid progress in the understanding and management of multiple sclerosis. With the support of magnetic resonance imaging early diagnosis is possible, enabling treatment initiation at the time of the first clinical attack. As most of the disease-modifying drugs are associated with adverse events, patients and clinicians need to weigh the benefit and safety of the various early treatment options before taking informed decisions.

OBJECTIVES: 1. to estimate the benefit and safety of disease-modifying drugs that have been evaluated in all studies (randomised or non-randomised) for the treatment of a first clinical attack suggestive of MS compared either with placebo or no treatment;2. to assess the relative efficacy and safety of disease-modifying drugs according to their benefit and safety;3. to estimate the benefit and safety of disease-modifying drugs that have been evaluated in all studies (randomised or non-randomised) for treatment started after a first attack ('early treatment') compared with treatment started after a second attack or at another later time point ('delayed treatment').

SEARCH METHODS: We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, MEDLINE, Embase, CINAHL, LILACS, clinicaltrials.gov, the WHO trials registry, and US Food and Drug Administration (FDA) reports, and searched for unpublished studies (until December 2016).

SELECTION CRITERIA: We included randomised and observational studies that evaluated one or more drugs as monotherapy in adult participants with a first clinical attack suggestive of MS. We considered evidence on alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta-1b, interferon beta-1a (Rebif®, Avonex®), laquinimod, mitoxantrone, natalizumab, ocrelizumab, pegylated interferon beta-1a, rituximab and teriflunomide.

DATA COLLECTION AND ANALYSIS: Two teams of three authors each independently selected studies and extracted data. The primary outcomes were disability-worsening, relapses, occurrence of at least one serious adverse event (AE) and withdrawing from the study or discontinuing the drug because of AEs. Time to conversion to clinically definite MS (CDMS) defined by Poser diagnostic criteria, and probability to discontinue the treatment or dropout for any reason were recorded as secondary outcomes. We synthesized study data using random-effects meta-analyses and performed indirect comparisons between drugs. We calculated odds ratios (OR) and hazard ratios (HR) along with relative 95% confidence intervals (CI) for all outcomes. We estimated the absolute effects only for primary outcomes. We evaluated the credibility of the evidence using the GRADE system.

MAIN RESULTS: We included 10 randomised trials, eight open-label extension studies (OLEs) and four cohort studies published between 2010 and 2016. The overall risk of bias was high and the reporting of AEs was scarce. The quality of the evidence associated with the results ranges from low to very low. Early treatment versus placebo during the first 24 months' follow-upThere was a small, non-significant advantage of early treatment compared with placebo in disability-worsening (6.4% fewer (13.9 fewer to 3 more) participants with disability-worsening with interferon beta-1a (Rebif®) or teriflunomide) and in relapses (10% fewer (20.3 fewer to 2.8 more) participants with relapses with teriflunomide). Early treatment was associated with 1.6% fewer participants with at least one serious AE (3 fewer to 0.2 more). Participants on early treatment were on average 4.6% times (0.3 fewer to 15.4 more) more likely to withdraw from the study due to AEs. This result was mostly driven by studies on interferon beta 1-b, glatiramer acetate and cladribine that were associated with significantly more withdrawals for AEs. Early treatment decreased the hazard of conversion to CDMS (HR 0.53, 95% CI 0.47 to 0.60). Comparing active interventions during the first 24 months' follow-upIndirect comparison of interferon beta-1a (Rebif®) with teriflunomide did not show any difference on reducing disability-worsening (OR 0.84, 95% CI 0.43 to 1.66). We found no differences between the included drugs with respect to the hazard of conversion to CDMS. Interferon beta-1a (Rebif®) and teriflunomide were associated with fewer dropouts because of AEs compared with interferon beta-1b, cladribine and glatiramer acetate (ORs range between 0.03 and 0.29, with substantial uncertainty). Early versus delayed treatmentWe did not find evidence of differences between early and delayed treatments for disability-worsening at a maximum of five years' follow-up (3% fewer participants with early treatment (15 fewer to 11.1 more)). There was important variability across interventions; early treatment with interferon beta-1b considerably reduced the odds of participants with disability-worsening during three and five years' follow-up (OR 0.52, 95% CI 0.32 to 0.84 and OR 0.57, 95% CI 0.36 to 0.89). The early treatment group had 19.6% fewer participants with relapses (26.7 fewer to 12.7 fewer) compared to late treatment at a maximum of five years' follow-up and early treatment decreased the hazard of conversion to CDMS at any follow-up up to 10 years (i.e. over five years' follow-up HR 0.62, 95% CI 0.53 to 0.73). We did not draw any conclusions on long-term serious AEs or discontinuation due to AEs because of inadequacies in the available data both in the included OLEs and cohort studies.

AUTHORS' CONCLUSIONS: Very low-quality evidence suggests a small and uncertain benefit with early treatment compared with placebo in reducing disability-worsening and relapses. The advantage of early treatment compared with delayed on disability-worsening was heterogeneous depending on the actual drug used and based on very low-quality evidence. Low-quality evidence suggests that the chances of relapse are less with early treatment compared with delayed. Early treatment reduced the hazard of conversion to CDMS compared either with placebo, no treatment or delayed treatment, both in short- and long-term follow-up. Low-quality evidence suggests that early treatment is associated with fewer participants with at least one serious AE compared with placebo. Very low-quality evidence suggests that, compared with placebo, early treatment leads to more withdrawals or treatment discontinuation due to AEs. Difference between drugs on short-term benefit and safety was uncertain because few studies and only indirect comparisons were available. Long-term safety of early treatment is uncertain because of inadequately reported or unavailable data.

References

  1. Arch Neurol. 1999 Jun;56(6):661-3 - PubMed
  2. N Engl J Med. 2000 Sep 28;343(13):898-904 - PubMed
  3. Lancet. 2001 May 19;357(9268):1576-82 - PubMed
  4. Am J Ophthalmol. 2001 Oct;132(4):463-71 - PubMed
  5. Neurology. 2002 Jan 22;58(2):169-78 - PubMed
  6. Ann Neurol. 2002 Apr;51(4):481-90 - PubMed
  7. Mult Scler. 2002 Aug;8(4):330-8 - PubMed
  8. Mult Scler. 2002 Oct;8(5):405-9 - PubMed
  9. J Clin Invest. 2003 Apr;111(8):1133-45 - PubMed
  10. Clin Immunol. 2003 Mar;106(3):163-74 - PubMed
  11. Ann Neurol. 2003 Jun;53(6):718-24 - PubMed
  12. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  13. Clin Ther. 2003 Nov;25(11):2865-74 - PubMed
  14. BMJ. 2004 Jun 19;328(7454):1490 - PubMed
  15. Arch Neurol. 2004 Oct;61(10):1515-20 - PubMed
  16. Lancet. 2004 Oct 23-29;364(9444):1489-96 - PubMed
  17. Neurology. 2004 Dec 28;63(12 Suppl 6):S15-8 - PubMed
  18. Neurology. 2006 Mar 14;66(5):678-84 - PubMed
  19. Neurology. 2006 Oct 10;67(7):1242-9 - PubMed
  20. Clin Neurol Neurosurg. 2007 May;109(4):344-9 - PubMed
  21. Acta Neurol Scand. 2007 Jun;115(6):429-31 - PubMed
  22. Lancet. 2007 Aug 4;370(9585):389-97 - PubMed
  23. Stat Med. 2008 Feb 28;27(5):711-27 - PubMed
  24. Arch Neurol. 2007 Sep;64(9):1292-8 - PubMed
  25. J Neurol. 2008 Apr;255(4):480-7 - PubMed
  26. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278 - PubMed
  27. Clin Trials. 2008;5(3):225-39 - PubMed
  28. Neurol Sci. 2009 Feb;30(1):21-31 - PubMed
  29. J Neurol. 2009 Jul;256(7):1061-6 - PubMed
  30. Brain. 2009 May;132(Pt 5):1175-89 - PubMed
  31. Mult Scler. 2009 Jun;15(6):728-34 - PubMed
  32. Lancet Neurol. 2009 Nov;8(11):987-97 - PubMed
  33. Lancet. 2009 Oct 31;374(9700):1503-11 - PubMed
  34. Arch Neurol. 2009 Nov;66(11):1345-52 - PubMed
  35. Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101 - PubMed
  36. Eur J Neurol. 2010 Jun 1;17(6):852-60 - PubMed
  37. J Neuroinflammation. 2010 May 19;7:30 - PubMed
  38. Neurology. 2010 Jun 8;74(23):1860-7 - PubMed
  39. Neuropsychiatr Dis Treat. 2010 Oct 05;6:619-25 - PubMed
  40. Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35 - PubMed
  41. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794 - PubMed
  42. Brain. 2011 Mar;134(Pt 3):678-92 - PubMed
  43. Clin Immunol. 2012 Jan;142(1):49-56 - PubMed
  44. Ann Neurol. 2011 Feb;69(2):292-302 - PubMed
  45. Nat Med. 2011 May;17(5):604-9 - PubMed
  46. Theranostics. 2011 Feb 17;1:154-88 - PubMed
  47. CNS Drugs. 2011 Jun 1;25(6):491-502 - PubMed
  48. J Clin Pharmacol. 2012 Jun;52(6):798-808 - PubMed
  49. Clin Ther. 2011 Jul;33(7):914-25 - PubMed
  50. Neurology. 2011 Aug 30;77(9):835-43 - PubMed
  51. Arch Neurol. 2012 Feb;69(2):183-90 - PubMed
  52. Lancet. 2011 Nov 19;378(9805):1779-87 - PubMed
  53. Lancet Neurol. 2012 Jan;11(1):33-41 - PubMed
  54. BMC Med Inform Decis Mak. 2012 Mar 16;12:20 - PubMed
  55. Mult Scler. 2012 Oct;18(10):1466-71 - PubMed
  56. PLoS One. 2012;7(6):e38661 - PubMed
  57. Mult Scler. 2013 Jul;19(8):1074-83 - PubMed
  58. J Neurol. 2013 Jun;260(6):1583-93 - PubMed
  59. JAMA Neurol. 2013 Feb;70(2):214-22 - PubMed
  60. Stat Med. 2013 Jul 30;32(17):2935-49 - PubMed
  61. Eur Neurol. 2013;70(1-2):35-41 - PubMed
  62. Ther Clin Risk Manag. 2013;9:177-90 - PubMed
  63. BMC Med. 2013 Jul 04;11:159 - PubMed
  64. Mult Scler. 2014 Feb;20(2):234-42 - PubMed
  65. J Neurol Sci. 2013 Dec 15;335(1-2):5-8 - PubMed
  66. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9 - PubMed
  67. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):647-53 - PubMed
  68. J Neurol. 2014 Mar;261(3):490-9 - PubMed
  69. JAMA Neurol. 2014 Mar;71(3):306-14 - PubMed
  70. Mayo Clin Proc. 2014 Feb;89(2):225-40 - PubMed
  71. Lancet Neurol. 2014 Mar;13(3):257-67 - PubMed
  72. Exp Neurol. 2014 Dec;262 Pt A:66-71 - PubMed
  73. J Autoimmun. 2014 Nov;54:81-92 - PubMed
  74. J Clin Neurosci. 2014 Nov;21(11):1857-65 - PubMed
  75. Interact J Med Res. 2014 Jul 24;3(3):e12 - PubMed
  76. Health Expect. 2016 Jun;19(3):727-37 - PubMed
  77. Lancet Neurol. 2014 Oct;13(10):977-86 - PubMed
  78. Mult Scler. 2015 Apr;21(4):415-22 - PubMed
  79. Mult Scler. 2015 Jul;21(8):1013-24 - PubMed
  80. Mult Scler Relat Disord. 2014 Mar;3(2):147-55 - PubMed
  81. Brain. 2015 Jul;138(Pt 7):1863-74 - PubMed
  82. Ann Clin Transl Neurol. 2015 May;2(5):479-91 - PubMed
  83. Res Synth Methods. 2015 Mar;6(1):45-62 - PubMed
  84. Res Synth Methods. 2012 Jun;3(2):80-97 - PubMed
  85. Pract Neurol. 2015 Aug;15(4):273-9 - PubMed
  86. Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381 - PubMed
  87. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 01;2(6):e158 - PubMed
  88. Ther Adv Neurol Disord. 2015 Nov;8(6):274-93 - PubMed
  89. Lancet Neurol. 2016 Mar;15(3):292-303 - PubMed
  90. BMC Neurol. 2016 Mar 02;16:30 - PubMed
  91. PLoS One. 2016 Mar 31;11(3):e0152347 - PubMed
  92. Neurology. 2016 Sep 6;87(10):978-87 - PubMed
  93. BMJ. 2016 Oct 12;355:i4919 - PubMed
  94. Mult Scler. 2017 Sep;23(10):1346-1357 - PubMed
  95. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294 - PubMed
  96. Neurology. 1983 Nov;33(11):1444-52 - PubMed
  97. Ann Neurol. 1983 Mar;13(3):227-31 - PubMed

Substances

MeSH terms

Publication Types